CAD SPECTRAL Technologies logo CAD SPECTRAL Technologies

Smart Screening.
Zero Invasion.
Your eyes tell the story.

We are developing SPECTRA-Mini — a non-invasive, eye-based screening approach designed to help detect early risk of coronary artery disease and improve access to cardiovascular assessment.

🚧 Coming soon

The problem

Coronary artery disease remains a leading cause of preventable death, yet it is often diagnosed late — particularly in regional and remote communities where access to advanced cardiac diagnostics is limited.

Current pathways rely on expensive, centralized tests and complex referrals, creating long wait times and missed opportunities for earlier intervention.

The solution

SPECTRA-Mini leverages advanced ocular imaging and data-driven analysis to extract cardiovascular insights from the eye — enabling rapid, painless screening without needles, radiation, or contrast agents.

Non-invasive
Fast & clinic-friendly
Designed for remote access
Data-driven risk insights
Clinical evidence (early): Our approach is being clinically validated against standard-of-care cardiovascular assessment pathways, with a focus on safety, accuracy, and real-world usability.

SPECTRA-Mini

A compact platform designed for primary care and community settings — bringing cardiovascular screening closer to where patients live.

SPECTRA-Mini device

Prototype concept image shown. Final design subject to iterative engineering and clinical feedback.

Designed for deployment

We’re optimizing form factor, workflow, and portability to support screening in metro, regional, and remote environments.

Portable footprint
Simple workflow
Clinic-ready UI
Scalable deployment

Want the latest updates? Email us at hadi.afsharan@gmail.com.

Why it matters

By shifting cardiovascular screening upstream, CAD SPECTRAL Technologies aims to reduce preventable heart attacks, improve health equity, and support clinicians with actionable insights earlier in the care pathway.

Expert WA-Based Team

A multidisciplinary founding team combining cardiology, optical engineering, and clinical translation — based in Western Australia.

Professor Girish Dwivedi

Professor Girish Dwivedi

MD, DM, MRCP, PhD, CCST (Cardiology), FESC, FASE, FRACP

Co-Founder and CMO
  • Wesfarmers Chair in Cardiology, Harry Perkins Institute of Medical Research & The University of Western Australia
  • Consultant Cardiologist, Fiona Stanley Hospital
Associate Professor Barry Cense

Assoc. Professor Barry Cense

BSc, PhD

Co-Founder and CTO
  • Director, Optical and Biomedical Engineering Labs (OBEL), The University of Western Australia
  • PhD in optical and biomedical engineering; PS-OCT expert; SPECTRA™ platform developer
Dr Hadi Afsharan

Dr Hadi Afsharan

BSc, MSc, PhD

Co-Founder and CSO
  • Research Fellow, Harry Perkins Institute of Medical Research & The University of Western Australia
  • FHRI Translational Fellow; biomedical engineering and clinical translation expert

About Us

A new way to see heart disease.

Heart disease often arrives quietly. No warning. No dramatic symptoms. Just subtle signs that are easy to miss — until it’s too late.

At CAD SPECTRAL Technologies, we believe early detection should be simple, accessible, and non-invasive. No needles. No radiation. No long hospital journeys. Just a quick eye scan that may reveal what’s happening in the heart.

The idea behind CAD SPECTRAL began with a simple but powerful insight: the eye is a window to the vascular system. Changes in blood vessels and tissue structure in the retina can reflect changes happening throughout the body — including the heart.

Why “CAD SPECTRAL”?

The name CAD reflects both our mission and our people. It stands for Coronary Artery Disease — the condition we aim to detect earlier — and the initials of our three founders: Cense, Afsharan, and Dwivedi.

The founders

Barry Cense brings decades of experience in advanced eye-imaging technologies, including OCT and polarisation-sensitive OCT, helping us see biological detail invisible to conventional scans.

Hadi Afsharan has spent his research career uncovering links between retinal microstructure and cardiovascular disease — driven by a desire to turn complex science into tools that genuinely help patients.

Girish Dwivedi is a leading cardiologist who sees, every day, the consequences of late diagnosis — and is passionate about bringing innovative, patient-friendly screening into real clinical care.

Why we exist

When the team came together in 2023, they shared a common frustration: too many people are diagnosed with heart disease only after a heart attack. This is especially true in regional and remote communities, where access to advanced cardiac testing is limited.

Our journey

2023
Founding team formed around a shared frustration with late diagnosis of coronary artery disease, particularly in regional and remote communities.
2024
Early prototype development and initial clinical translation work, building on advances in ocular imaging and cardiovascular research.
2025
Clinical validation activities underway, with a focus on usability, safety, and real-world deployment pathways.
Now
Advancing SPECTRA-Mini toward scalable, non-invasive cardiovascular screening for primary care and community settings.

CAD SPECTRAL Technologies was created to change that reality.

Our vision is a future where a simple eye scan can help flag cardiovascular risk early — giving people time, choice, and the chance to act before a life-changing event occurs.

Because behind every diagnosis is a person.
And behind every early detection is a life that could be saved.